首页 | 本学科首页   官方微博 | 高级检索  
检索        

我国生物类似药相关法规体系研究的总体原则
引用本文:邵颖,杨建红,李洁,张象麟.我国生物类似药相关法规体系研究的总体原则[J].现代药物与临床,2019,34(4):877-882.
作者姓名:邵颖  杨建红  李洁  张象麟
作者单位:沈阳药科大学 亦弘商学院,北京,100027;辉瑞投资有限公司,北京,100000
摘    要:生物类似药法规体系研究在我国尚属空白。为保证研究方向的质量,确立了我国生物类似药相关法规体系研究的总体原则:以解决国内患者生物制品药物的可及性为核心目标、以遵循生物类似药研发规律为原则、以夯实生物制品民族产业基础为出发点、汲取化药仿制药产业发展的经验教训以及研究建议的可操性。主要对我国生物类似药相关法规体系研究的总体原则进行阐述。

关 键 词:生物类似药  法规体系  总体原则
收稿时间:2019/3/5 0:00:00

General principles for the research of the legal system of bio-similar drugs in China
SHAO Ying,YANG Jian-hong,LI Jie and ZHANG Xiang-lin.General principles for the research of the legal system of bio-similar drugs in China[J].Drugs & Clinic,2019,34(4):877-882.
Authors:SHAO Ying  YANG Jian-hong  LI Jie and ZHANG Xiang-lin
Institution:School of Yeehong Business, Shenyang Pharmaceutical University, Beijing 100027, China,School of Yeehong Business, Shenyang Pharmaceutical University, Beijing 100027, China,Pfizer Investment Co., Ltd., Beijing 100000, China and School of Yeehong Business, Shenyang Pharmaceutical University, Beijing 100027, China
Abstract:The research on the regulatory system of biosimilar drugs is still a blank in China. To ensure the quality of the research direction, the general principles of relevant laws and regulations system of bio-similar drugs are established in China:in order to solve the domestic biological products in patients with drug accessibility as the core goal, in order to follow the principle of bio-similar drugs research and development of biological products, in order to strengthen national industrial base as the starting point, draw experiences and lessons from the generic medicines industry development, and research suggests that can hold. The general principles of relevant laws and regulations system of bio-similar drugs in China are reviewed in this paper.
Keywords:bio-similar drug  legal principle  general principle
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号